{"success":true,"data":{"pressRelease":{"id":"131489","rtpr_id":"nGNX2Dp8p1","ticker":"SPRC","exchange":"NASDAQ","all_tickers":["SPRC"],"title":"SciSparc: Subsidiary NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial","author":"Globe Newswire","published_at":"2026-08-31T20:03:00.096Z","article_body":"TEL AVIV, Israel, Aug. 31, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq:\nSPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs\nInc. (TSXV: NTLX) (\"NeuroThera\"), a clinical-stage pharmaceutical company\nfocused on developing novel treatments for central nervous system disorders,\ncontinued advancement in participant enrollment for the clinical trial\nassessing NeuroThera’s innovative SCI-210 treatment for symptoms associated\nwith autism spectrum disorder (“ASD”).\n\nThe clinical trial, conducted at Soroka Medical Center in Israel, is a\ndouble-blind, randomized, placebo-controlled study evaluating the safety and\nefficacy of SCI-210 in children diagnosed with ASD. To date, 26 children have\nbeen enrolled, marking strong progress toward the planned total of 60 children\nbetween the ages of five and 18, each of whom will receive treatment over a\n20-week period.\n\nSCI-210 is an innovative proprietary combination of cannabidiol (“CBD”)\nand CannAmide™, NeuroThera’s Palmitoylethanolamide-based proprietary\nformulation. The treatment is being assessed for its ability to alleviate\nsymptoms associated with ASD and to determine whether the dual‑compound\napproach offers advantages beyond CBD monotherapy.\n\nThe study is designed to evaluate the efficacy and safety of SCI-210 compared\nwith CBD monotherapy. The trial’s primary efficacy endpoints include the\nAberrant Behavior Checklist-Community (ABC-C) parent questionnaire, the\nClinical Global Impressions-Improvement (CGI-I) assessment conducted by a\nclinician, and determination of the optimal therapeutic dose.\n\nThe ongoing clinical trial is a key element of NeuroThera’s program for\nSCI-210 and reflects NeuroThera’s broader commitment to advancing innovative\ntreatments for neurological and neurodevelopmental conditions. The study was\ndesigned in collaboration with the National Autism Research Center, a leading\nauthority on autism research in Israel.\n\nSubject to the successful completion of the clinical development program and\nreceipt of applicable regulatory approvals, NeuroThera intends to pursue the\ncommercialization of SCI-210, initially in Israel and subsequently in\nadditional markets.\n\nAbout SciSparc Ltd. (Nasdaq: SPRC):\n\nThe Company, through its subsidiary NeuroThera, engages in clinical-stage\npharmaceutical developments. SciSparc’s focus is on creating and enhancing a\nportfolio of technologies and assets based on cannabinoid pharmaceuticals.\nWith this focus, the Company, together with its majority-owned subsidiary\nNeuroThera, is currently engaged in the following drug development programs\nbased on THC and/or non-psychoactive CBD: SCI-110 for the treatment of\nTourette syndrome, for the treatment of Alzheimer's disease and agitation; and\nSCI- 210 for the treatment of autism spectrum disorder and status epilepticus.\nThe Company, through NeuroThera, also owns a controlling interest in a\nsubsidiary whose business focuses on the sale of hemp seed oil-based products\non the Amazon.com\n(https://www.globenewswire.com/Tracker?data=akeGJkglvKGJTWZq7KXh6-6xFg9q3hsM-jP1VanfoosXA6wmKwrckiHriVFLB5zcK7LdT-P7FvmYM-qy3u2dew==) Marketplace.\n\nAbout NeuroThera Labs Inc.\n\nNeuroThera is a clinical-stage pharmaceutical company focused on developing\nnovel therapeutics for central nervous system disorders and other underserved\nhealth conditions through collaborations and innovative combinations.\n\nForward-Looking Statements:\n\nThis press release contains forward-looking statements within the meaning of\nthe “safe harbor” provisions of the Private Securities Litigation Reform\nAct of 1995 and other Federal securities laws. For example, SciSparc uses\nforward-looking statements when it discusses t the continued progress and\ntiming of participant enrollment in NeuroThera's clinical trial of SCI-210,\nincluding NeuroThera's ability to enroll the planned total of 60 children; the\ndesign, conduct, duration and completion of the clinical trial, including the\n20-week treatment period; the potential of SCI-210 to alleviate symptoms\nassociated with autism spectrum disorder; whether the combination of CBD and\nCannAmide™ offers advantages over CBD monotherapy; the ability of the trial\nto demonstrate the efficacy and safety of SCI-210, to meet its primary\nefficacy endpoints and to determine an optimal therapeutic dose; NeuroThera's\nbroader development plans for SCI-210 and other treatments for neurological\nand neurodevelopmental conditions; and NeuroThera's intention to pursue\nregulatory approval and commercialization of SCI-210, initially in Israel and\nsubsequently in additional markets.\n\nThe forward-looking statements contained or implied in this press release are\nsubject to other risks and uncertainties, including those discussed under the\nheading “Risk Factors” in SciSparc’s Annual Report on Form 20-F, filed\nwith the SEC on April 29, 2026, as amended on August 19, 2026, and in\nsubsequent filings with the U.S. Securities and Exchange Commission. Except as\notherwise required by law, SciSparc disclaims any intention or obligation to\nupdate or revise any forward-looking statements, which speak only as of the\ndate they were made, whether as a result of new information, future events or\ncircumstances or otherwise.\n\nInvestor Contact:\nIR@scisparc.com\nTel: +972-3-6167055\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/bcad2b2c-74a6-4d74-b0f3-6f42a3c00a90)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX2Dp8p1","title":"SciSparc: Subsidiary NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial","author":"Globe Newswire","ticker":"SPRC","created":"2026-08-31T20:03:00.096Z","tickers":["SPRC"],"exchange":"NASDAQ","article_body":"TEL AVIV, Israel, Aug. 31, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq:\nSPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs\nInc. (TSXV: NTLX) (\"NeuroThera\"), a clinical-stage pharmaceutical company\nfocused on developing novel treatments for central nervous system disorders,\ncontinued advancement in participant enrollment for the clinical trial\nassessing NeuroThera’s innovative SCI-210 treatment for symptoms associated\nwith autism spectrum disorder (“ASD”).\n\nThe clinical trial, conducted at Soroka Medical Center in Israel, is a\ndouble-blind, randomized, placebo-controlled study evaluating the safety and\nefficacy of SCI-210 in children diagnosed with ASD. To date, 26 children have\nbeen enrolled, marking strong progress toward the planned total of 60 children\nbetween the ages of five and 18, each of whom will receive treatment over a\n20-week period.\n\nSCI-210 is an innovative proprietary combination of cannabidiol (“CBD”)\nand CannAmide™, NeuroThera’s Palmitoylethanolamide-based proprietary\nformulation. The treatment is being assessed for its ability to alleviate\nsymptoms associated with ASD and to determine whether the dual‑compound\napproach offers advantages beyond CBD monotherapy.\n\nThe study is designed to evaluate the efficacy and safety of SCI-210 compared\nwith CBD monotherapy. The trial’s primary efficacy endpoints include the\nAberrant Behavior Checklist-Community (ABC-C) parent questionnaire, the\nClinical Global Impressions-Improvement (CGI-I) assessment conducted by a\nclinician, and determination of the optimal therapeutic dose.\n\nThe ongoing clinical trial is a key element of NeuroThera’s program for\nSCI-210 and reflects NeuroThera’s broader commitment to advancing innovative\ntreatments for neurological and neurodevelopmental conditions. The study was\ndesigned in collaboration with the National Autism Research Center, a leading\nauthority on autism research in Israel.\n\nSubject to the successful completion of the clinical development program and\nreceipt of applicable regulatory approvals, NeuroThera intends to pursue the\ncommercialization of SCI-210, initially in Israel and subsequently in\nadditional markets.\n\nAbout SciSparc Ltd. (Nasdaq: SPRC):\n\nThe Company, through its subsidiary NeuroThera, engages in clinical-stage\npharmaceutical developments. SciSparc’s focus is on creating and enhancing a\nportfolio of technologies and assets based on cannabinoid pharmaceuticals.\nWith this focus, the Company, together with its majority-owned subsidiary\nNeuroThera, is currently engaged in the following drug development programs\nbased on THC and/or non-psychoactive CBD: SCI-110 for the treatment of\nTourette syndrome, for the treatment of Alzheimer's disease and agitation; and\nSCI- 210 for the treatment of autism spectrum disorder and status epilepticus.\nThe Company, through NeuroThera, also owns a controlling interest in a\nsubsidiary whose business focuses on the sale of hemp seed oil-based products\non the Amazon.com\n(https://www.globenewswire.com/Tracker?data=akeGJkglvKGJTWZq7KXh6-6xFg9q3hsM-jP1VanfoosXA6wmKwrckiHriVFLB5zcK7LdT-P7FvmYM-qy3u2dew==) Marketplace.\n\nAbout NeuroThera Labs Inc.\n\nNeuroThera is a clinical-stage pharmaceutical company focused on developing\nnovel therapeutics for central nervous system disorders and other underserved\nhealth conditions through collaborations and innovative combinations.\n\nForward-Looking Statements:\n\nThis press release contains forward-looking statements within the meaning of\nthe “safe harbor” provisions of the Private Securities Litigation Reform\nAct of 1995 and other Federal securities laws. For example, SciSparc uses\nforward-looking statements when it discusses t the continued progress and\ntiming of participant enrollment in NeuroThera's clinical trial of SCI-210,\nincluding NeuroThera's ability to enroll the planned total of 60 children; the\ndesign, conduct, duration and completion of the clinical trial, including the\n20-week treatment period; the potential of SCI-210 to alleviate symptoms\nassociated with autism spectrum disorder; whether the combination of CBD and\nCannAmide™ offers advantages over CBD monotherapy; the ability of the trial\nto demonstrate the efficacy and safety of SCI-210, to meet its primary\nefficacy endpoints and to determine an optimal therapeutic dose; NeuroThera's\nbroader development plans for SCI-210 and other treatments for neurological\nand neurodevelopmental conditions; and NeuroThera's intention to pursue\nregulatory approval and commercialization of SCI-210, initially in Israel and\nsubsequently in additional markets.\n\nThe forward-looking statements contained or implied in this press release are\nsubject to other risks and uncertainties, including those discussed under the\nheading “Risk Factors” in SciSparc’s Annual Report on Form 20-F, filed\nwith the SEC on April 29, 2026, as amended on August 19, 2026, and in\nsubsequent filings with the U.S. Securities and Exchange Commission. Except as\notherwise required by law, SciSparc disclaims any intention or obligation to\nupdate or revise any forward-looking statements, which speak only as of the\ndate they were made, whether as a result of new information, future events or\ncircumstances or otherwise.\n\nInvestor Contact:\nIR@scisparc.com\nTel: +972-3-6167055\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/bcad2b2c-74a6-4d74-b0f3-6f42a3c00a90)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-08-31T20:03:00.155833907Z","server_sent_at_ms":1788206580155},"received_at":"2026-08-31T20:03:00.214Z","source_url":null},"analysis":{"id":"120389","press_release_id":"131489","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"clinical_trial","narrative":"SciSparc announced that its subsidiary NeuroThera Labs has enrolled 26 children in a clinical trial for SCI-210, targeting a total of 60 patients to evaluate the treatment for autism spectrum disorder.\n\nThe double-blind, placebo-controlled study is assessing the safety and efficacy of the proprietary CBD and CannAmide combination over a 20-week period at Soroka Medical Center in Israel.\n\nSubject to regulatory approval, NeuroThera plans to commercialize SCI-210 initially in Israel and expand to additional markets thereafter.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Enrollment milestone reached for subsidiary's autism drug trial."},"keyFigures":{"customDimensions":{"enrolled_patients":26,"patient_age_range":"5-18","target_enrollment":60,"treatment_duration_weeks":20}},"quotedText":"","namedEntities":{"people":[],"products":["SCI-210","CannAmide","cannabidiol"],"companies":[{"name":"SciSparc Ltd.","ticker":"SPRC"},{"name":"NeuroThera Labs Inc.","ticker":"NTLX","relationship":"subsidiary"},{"name":"Soroka Medical Center","relationship":"trial site"},{"name":"National Autism Research Center","relationship":"collaborator"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Routine operational update reporting enrollment progress in a small clinical trial (26 of 60 patients) for a subsidiary's drug candidate. Positive but not a binary event or top-line data readout."},"tickerRelevance":{"others":[{"ticker":"NTLX","relevance":"subsidiary"}],"primary":"SPRC"},"globalImportance":15,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"trial_enrollment_update"}},"event_type":"clinical_trial","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"SciSparc announced that its subsidiary NeuroThera Labs has enrolled 26 children in a clinical trial for SCI-210, targeting a total of 60 patients to evaluate the treatment for autism spectrum disorder.\n\nThe double-blind, placebo-controlled study is assessing the safety and efficacy of the proprietary CBD and CannAmide combination over a 20-week period at Soroka Medical Center in Israel.\n\nSubject to regulatory approval, NeuroThera plans to commercialize SCI-210 initially in Israel and expand to additional markets thereafter.","key_figures":{"customDimensions":{"enrolled_patients":26,"patient_age_range":"5-18","target_enrollment":60,"treatment_duration_weeks":20}},"named_entities":{"people":[],"products":["SCI-210","CannAmide","cannabidiol"],"companies":[{"name":"SciSparc Ltd.","ticker":"SPRC"},{"name":"NeuroThera Labs Inc.","ticker":"NTLX","relationship":"subsidiary"},{"name":"Soroka Medical Center","relationship":"trial site"},{"name":"National Autism Research Center","relationship":"collaborator"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-08-31T20:07:58.804Z","global_importance":15,"audience_relevance":15,"importance_components":{"tickerTier":"micro-cap","eventGravity":"trial_enrollment_update"}},"durationMs":214740,"modelName":"glm-4.7"}}